strona główna > informacje dla lekarzy > pogl±dy > ci¶nienie a udary > pi¶miennictwo
informacje dla lekarzy


PI¦MIENNICTWO


  1. Murray JL, Lopez AD.Mortality by cause for eight regions of the world: Global burden of disease study. Lancet. 1997;349:1269-1276.
  2. Samsa GP, Bian J, Lipscomb J, Matchar D.Epidemiology of recurrent cerebral infarction & medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999;30:338-349.
  3. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology. 1997;48:891-895.
  4. Chalmers J, Mac Mahon S, Anderson C, Neal B, Rodgers A. Clinican’s Manual on Blood Pressure and Stroke Prevention. London: Science Press; 1996.
  5. MacMahon S, Rodgers A. The effects of antihyperten-sive treatment on vascular disease: Reappraisal of the evidence in 1994. J Vasc Med Biol. 1993;4:265-271.
  6. MacMahon S, Rodgers A. Blood pressure, antihyper-tensive treatment and stroke risk. J Hypertens. 1994;12(suppl 10):S5-S14.
  7. O’Brien AA, Rajkumar C, Bulpitt CJ. Blood pressure lowering for the primary and secondary prevention of stoke: treatment of hypertension reduces the risk of stroke. J Cardiovasc Risk. 1999,6:203-205.
  8. Horne M, Carson NE. Medi+CAL Stroke CD ROM.1999.
  9. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
  10. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA)aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
  11. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
  12. MacMahon S, Neal B, Rodgers A. Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease. Schweiz Med Wochenschr. 1995;125:2479-2486.
  13. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.
  14. Effect of antihypertensive treatment on stroke recur-rence. Hypertension-Stroke Cooperative Study Group. JAMA. 1974;229:409-418.
  15. TEST Group.Cerebrovasc Dis.1995;5:21-25.
  16. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Study Group. Stroke. 1993;24:543-548.
  17. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780-786.
  18. Myers GM. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol. 1996;12:1191-1196.
  19. Dyker AG, Grosset DG, Lees KR. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke. 1997;28:580-583.
  20. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo ontrolled study. Br Heart J. 1991;66:206-211.
  21. Kool MJ, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens. 1995;13:839-848.
  22. PROGRESS Results. From paper presented at: Annual Meeting of the European Society of Hypertension. June 15, 1999;Milan,Italy.
  23. PROGRESS Results. Data on file.
  24. Fox K, Remme W. ACE Inhibition and Ischaemic Heart Disease. London: Science Press;1999.
  25. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733-743.
  26. Morgan T, Anderson A. Clinical efficacy of perindopril in hypertension. Clin Exp Pharmacol Physiol. 1992;19(Suppl 19):61-65.
  27. Morgan T, Anderson A. Duration of antihypertensive effect of perindopril, enalapril and captopril. Hypertension. 1993;21:568.
  28. Squire IB, MacFadyen RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol. 1996;27:657-666.
  29. Navookarasu NT, Rahman AR, Adbullah I. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac faiure: a Malaysian experience. Int J C in Pract. 1999;53:25-30.
  30. Lees KR, Walter MR, Bolster A, Dyker AG, Lees KR. The effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke. 2000. In Press.
  31. Cohn JN. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhyth-mias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87(Suppl 7):110-114.
  32. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension .1995;25:474-481.
  33. Chillon JM, Baumbach GL. Proceedings in Milan-ESH-8th European Meeting on Hypertension. 13-16 June 1997;8B:4.
  34. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arterioles in rats. Hypertension. 1999;33:856-861.
  35. Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and athero-sclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol.1996;23(suppl 1):S30-S32.
  36. Lehman ED, Hopkins KD, Jones RL, Rudd AG, Gosling RG. Aortic distensibility in patients with cerebrovascular disease. Clin Sci(Colch). 1995;89:247-253.
  37. Asmar R. Arterial Stiffness And Pulse Wave Velocity. Clinical Applications. Paris: Elsevier; 1999.
  38. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation. 1988;78:941-950.
  39. Kool MJ, Lustermans FA, Breed JG, et al. Effect of perindopril and amiloride/hydrochlorothiazide on haemodynamics wessel wall properties of large arteries. J Hypertens. 1999;(Suppl 5):S362-S363.
  40. Tendera M., Korewicki J., Wrabec K., Wysocki H., Oral preservation, PTK, 1999.09.18
  41. Vitovec J., Spinar J., First-dose hypotension after angiotensin-converting enzyme (ACE)inhibitors in chronic heart failure: a comparison of enalapril and perindopril. European Journal of Heart Failure 2;2000;299-304.
  42. USA Monographs.
  43. Günzel P., et al., Journal Cardiov Pharmac. 1991;17:8-12.
  44. Morgan T., Br J Cardiol. 1995 suppl. 1,57-59.


    << wstecz | spis tre¶ci

Strona główna | Dla lekarzy | Informacje ogólne | Dla dziennikarzy | Biuletyn | Szukaj | Nota prawna